argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
argenx SE - American Depositary Shares (ARGX)
US:NASDAQ Investor Relations:
investor.argenx.com/phoenix.zhtml?c=254223&p=irol-presentations
Company Research
Source: GlobeNewswire
$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in 2026 from leading immunology pipeline Management to host conference call today at 1:30 PM CET (8:30 AM ET) October 30, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its third quarter 2025 financial results and provided a business update. “argenx continues to deliver on our bold innovation agenda, driving transformational impact for patients worldwide,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “This year, we expanded our global reach with VYVGART in two blockbuster indications, advanced five registrational programs, and are on track to complete
Show less
Read more
Impact Snapshot
Event Time:
ARGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARGX alerts
High impacting argenx SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ARGX
News
- argenex (NASDAQ:ARGX) had its price target raised by analysts at Morgan Stanley from $1,070.00 to $1,110.00. They now have an "overweight" rating on the stock.MarketBeat
- argenex (NASDAQ:ARGX) had its "peer perform" rating reaffirmed by analysts at Wolfe Research.MarketBeat
- argenx Announces Results of Extraordinary General Meeting of ShareholdersGlobeNewswire
- argenex (NASDAQ:ARGX) had its price target raised by analysts at Citigroup Inc. from $1,041.00 to $1,124.00. They now have a "buy" rating on the stock.MarketBeat
- argenex (NASDAQ:ARGX) had its price target raised by analysts at Wedbush from $880.00 to $1,000.00. They now have an "outperform" rating on the stock.MarketBeat
ARGX
Earnings
- 10/30/25 - Beat
ARGX
Sec Filings
- 11/18/25 - Form 6-K
- 11/14/25 - Form SCHEDULE
- 10/30/25 - Form 6-K
- ARGX's page on the SEC website